JP2017509611A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509611A5
JP2017509611A5 JP2016553397A JP2016553397A JP2017509611A5 JP 2017509611 A5 JP2017509611 A5 JP 2017509611A5 JP 2016553397 A JP2016553397 A JP 2016553397A JP 2016553397 A JP2016553397 A JP 2016553397A JP 2017509611 A5 JP2017509611 A5 JP 2017509611A5
Authority
JP
Japan
Prior art keywords
alkyl
group
cycloalkyl
pharmaceutically acceptable
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509611A (ja
JP6434528B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053309 external-priority patent/WO2015124563A1/en
Publication of JP2017509611A publication Critical patent/JP2017509611A/ja
Publication of JP2017509611A5 publication Critical patent/JP2017509611A5/ja
Application granted granted Critical
Publication of JP6434528B2 publication Critical patent/JP6434528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553397A 2014-02-21 2015-02-17 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用 Active JP6434528B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14156159 2014-02-21
EP14156159.7 2014-02-21
PCT/EP2015/053309 WO2015124563A1 (en) 2014-02-21 2015-02-17 Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity

Publications (3)

Publication Number Publication Date
JP2017509611A JP2017509611A (ja) 2017-04-06
JP2017509611A5 true JP2017509611A5 (enExample) 2018-03-29
JP6434528B2 JP6434528B2 (ja) 2018-12-05

Family

ID=50137570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553397A Active JP6434528B2 (ja) 2014-02-21 2015-02-17 置換ピリドン及びピラジノン、並びに好中球エラスターゼ活性の阻害剤としてのその使用

Country Status (4)

Country Link
US (1) US9221807B2 (enExample)
EP (1) EP3107911B1 (enExample)
JP (1) JP6434528B2 (enExample)
WO (1) WO2015124563A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017207432A1 (en) * 2016-05-31 2017-12-07 Chiesi Farmaceutici S.P.A. Novel compounds
AR108609A1 (es) * 2016-05-31 2018-09-05 Chiesi Farm Spa Derivados de imidazolona y pirazolona como inhibidores de la elastasa de neutrófilos humana (hne)
PL3890828T3 (pl) * 2018-12-03 2025-06-16 Boehringer Ingelheim International Gmbh Związki heteroaromatyczne jako inhibitory wanin
AU2020349353A1 (en) 2019-09-17 2022-04-14 Duke University Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
ES2962498T3 (es) 2020-04-16 2024-03-19 Mereo Biopharma 4 Ltd Métodos que implican el inhibidor de elastasa de neutrófilos alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina
US20220242932A1 (en) * 2021-01-29 2022-08-04 DiaMedica USA Inc. Ulinastatin polypeptides for treating diseases
KR20240090272A (ko) 2021-10-20 2024-06-21 메레오 바이오파마 4 리미티드 섬유화 치료에 사용하기 위한 호중구 엘라스테이스 억제제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0605469D0 (en) * 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
AU2010302420B2 (en) 2009-10-02 2013-07-04 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase

Similar Documents

Publication Publication Date Title
JP2017509611A5 (enExample)
JP2016516020A5 (enExample)
JP2015526453A5 (enExample)
JP2013543896A5 (enExample)
JP2016511262A5 (enExample)
JP2017528503A5 (enExample)
JP2014511891A5 (enExample)
JP2015526455A5 (enExample)
JP2017504635A5 (enExample)
JP2017527578A5 (enExample)
JP2016520618A5 (enExample)
JP2014511892A5 (enExample)
JP2017528507A5 (enExample)
JP2012533546A5 (enExample)
JP2017504611A5 (enExample)
JP2012509263A5 (enExample)
JP2015526454A5 (enExample)
JP2011037901A5 (enExample)
JP2010501478A5 (enExample)
JP2014500265A5 (enExample)
JP2016507575A5 (enExample)
JP2018168191A5 (enExample)
JP2016510785A5 (enExample)
JP2010155827A5 (enExample)
JP2016515110A5 (enExample)